January 25, 2021
Business News

Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

REDWOOD CITY, Calif.–()–Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021.

The presentations will cover the use of Guardant Health’s liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.

“It is increasingly becoming evident that the value of our liquid biopsy in advanced cancer extends beyond simply tumor mutation…

Click here to view the original article.

Related Posts

You might also like ...

Market Outlook for the Virtual Schools Market in North America to 2024, Featuring Abbotsford Virtual School, Acklam Grange School, Basehor-Linwood Virtual School, Charter Schools USA and More – ResearchAndMarkets.com
Riassunto: La NATO sceglie Thales per la fornitura della prima soluzione cloud per la difesa delle forze armate
AON Splash Image
DAVOS 2021: COVID-19 crisis won’t end until developing nations get vaccine